Some uses of transition metal complexes as anti-cancer and anti-HIV agents
- 18 September 2007
- journal article
- perspective
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- No. 43,p. 4884-4892
- https://doi.org/10.1039/b705079h
Abstract
The success of the clinical uses of cisplatin, cis-[PtII(NH3)2Cl2], has stimulated considerable interest in using other metal complexes as new therapeutic agents. This perspective describes our recent work on several classes of gold(III), platinum(II), ruthenium(II, III, IV), iron(II) and vanadium(IV) complexes for anti-cancer and anti-HIV treatments.Keywords
This publication has 83 references indexed in Scilit:
- The inorganic side of chemical biologyNature Chemical Biology, 2006
- New metal complexes as potential therapeuticsCurrent Opinion in Chemical Biology, 2003
- Boon and Bane of Metal Ions in MedicineScience, 2003
- Biological inorganic chemistry at the beginning of the 21st centuryProceedings of the National Academy of Sciences, 2003
- New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNAProceedings of the National Academy of Sciences, 2003
- Medicinal Inorganic Chemistry: IntroductionChemical Reviews, 1999
- Medicinal Inorganic ChemistryAdvances in Inorganic Chemistry, 1999
- Metal Compounds in Therapy and DiagnosisScience, 1993
- Inorganic Chemistry and Drug DesignAdvances in Inorganic Chemistry, 1991
- Platinum Compounds: a New Class of Potent Antitumour AgentsNature, 1969